To provide the information your oncologist is not telling you or doesn't have the time to!
It’s been a while since my last post. That’s not for lack of news. These past several months have been some of the fullest of my life: clinic, program building, my directorship, speaking, consulting, the businesses my wife and I run together, and most importantly, being a husband and a dad to four kids. Writing …
A melanoma oncologist unpacks the new Phase 3 personalized mRNA cancer vaccine data — what it shows, what’s still unknown, and the questions patients are asking this week.
Sometimes the most important advances are not breakthroughs in biology, but breakthroughs in giving patients one more meaningful option.
Sometimes stepping back isn’t a setback — it’s a reset.
Curated science + real conversations = faster, safer implementation on Monday.
A hopeful reflection on RP1’s FDA setback and the future of intratumoral therapy in melanoma.
News broke today that President Joe Biden has been diagnosed with stage IV (metastatic) prostate cancer. As an oncologist, this is not just a headline—it becomes an important teaching moment for how we evaluate and manage newly diagnosed metastatic prostate cancer. With the public eye now focused, many are likely wondering: what does this diagnosis …
If you’ve ever picked up a brightly colored candy or a strawberry-flavored treat, chances are you’ve encountered Red Dye No. 3, a synthetic food dye known for its vibrant hue. Despite its eye-catching appeal, Red Dye No. 3 has long been surrounded by controversy due to potential health risks. Recently, the U.S. Food and Drug …
Prenatal cell-free DNA (cfDNA) testing has revolutionized obstetrics, serving primarily to screen for fetal genetic abnormalities. Similarly, in oncology, circulating tumor DNA (ctDNA) has become a vital tool for detecting minimal residual disease in colorectal cancer after resection and monitoring responses to immunotherapy. However, groundbreaking research published in the December 2024 issue of The New England …
On December 2, 2024, Novocure announced positive results from the Phase 3 PANOVA-3 trial, which evaluated Tumor Treating Fields (TTFields) therapy in combination with gemcitabine and nab-paclitaxel for unresectable, locally advanced pancreatic cancer. The trial demonstrated a statistically significant improvement in overall survival (OS), offering a new potential option for this challenging patient population. However, …